PRA Health Sciences was awarded grants and contracts to work with academic research institutions Washington University in St. Louis (Missouri) and the University of Washington in Seattle to provide on-demand project management, remote monitoring, and other clinical research services and support for COVID-19 studies.
These trials are made possible through funding from the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard to speed research and development efforts and access to therapies for COVID-19.
“We are proud to support the research teams who are developing therapeutics and prophylaxes for COVID-19,” said Kathleen Mandziuk, MPH, RN, Vice President, Digital Health, PRA Health Sciences. “These studies reflect the type of initiatives that further our mission to take on tough global challenges with organizations who have innovative ideas.”
As of September 2020, PRA is supporting three national and global COVID-19 trials funded by the Therapeutics Accelerator. One study, led by researchers at the University of Washington in Seattle, investigated hydroxychloroquine as a post-exposure prophylaxis (PEP) for patients who had close contact with someone who had a confirmed COVID-19 diagnosis, such as household contacts, medical staff, and first responders. The results, which were presented at IDWeek 2020, determined that those taking the drug were just as likely to test positive as were those taking the placebo. The findings will be published in Open Forum Infectious Diseases.
In another study, a global consortium of researchers led by Washington University School of Medicine in St. Louis are evaluating whether the measles, mumps and rubella (MMR) vaccine can be used as a pre-exposure prophylaxis (PrEP) for healthcare workers. This trial plans to enroll up to 30,000 participants across nine regions, including North America, Europe, and Africa.
PRA’s initial support includes project management, remote monitoring, patient recruitment, pharmacovigilance support, and clinical supply provisioning, with the flexibility to expand at any time into other operational areas and studies.
Clinical research is commonly initiated by sponsors such as pharmaceutical and biopharmaceutical companies, but can also be led by investigators, such as academic institutions and non-profit organizations. Investigator-led research can be complex and requires specialized project management experience.
PRA possesses the clinical development experience and expertise to assist all types of research, helping ensure project success by facilitating the clinical research process, resolving complex operational challenges, and navigating any uncertainties.
We are extremely proud to bring our expertise to the hallowed halls of these scholarly institutions that are committed to research to provide our leadership and oversight to the vital work they’re performing. The research that is taking place at these universities has the potential to help eradicate a deadly virus and put an end to a global health emergency.
Learn more about PRA’s investigator-initiated trials and the value of having a dedicated solution to improve the management of these important, complex studies.
In the second week of July, we bring you news of developments in HIV research, as well as updates on immunotherapies, Alzheimer’s disease,…
Ask the Experts: What is the Current Clinical Development for Respiratory Conditions?
COVID-19 is a disease that heavily affects the respiratory systems of those that contract the disease. Inspired by Respiratory Care Week, we must pay…
Recommendations on Writing a Clinical Study Report for a Study Conducted During the COVID-19 Pandemic
The clinical study report (CSR) is a crucial document in the drug development and regulatory submission process that describes the background,…